Prime Minister Narendra Modi has underscored a significant transformation underway in India’s pharmaceutical sector, stating that the country is evolving from being the “pharmacy of the world” to an emerging hub of innovation. Highlighting the sector’s growth trajectory, the Prime Minister emphasized that India is moving up the value chain by focusing on research-driven development rather than relying solely on generic drug manufacturing. 

India has long been recognized globally for supplying affordable medicines, particularly generic drugs. However, recent policy initiatives and industry efforts are increasingly geared toward strengthening innovation capabilities. The government has been encouraging investments in research and development, with a strong push toward biologics, biosimilars, and next-generation therapies. 

The remarks come alongside discussions highlighted during India Pharma 2026, where policymakers and industry leaders stressed the need for innovation-led growth and global competitiveness. The sector is also witnessing increased collaboration between academia and industry to accelerate scientific advancements. 

Modi’s statement reflects a broader vision of positioning India as a leader in cutting-edge pharmaceutical innovation, ensuring both domestic healthcare advancement and a stronger presence in the global life sciences industry.